Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Sorin divests peripheral stent business to Datascope

Sorin : 12 June, 2008  (Company News)
Sorin Group has divested its peripheral stent business to Datascope, which has become the new owner of the entire Sorin peripheral vascular stent product business worldwide.
Datascope also becomes the exclusive owner of a portfolio of intellectual property within the Endovascular Field of Use. As previously announced, Sorin Group plans to divest its non-core assets in order to better focus on its strategic businesses, cardiopulmonary, heart valves and CRM.

Sorin's innovative peripheral Stent products are dedicated to the treatment of peripheral arterial disease (PAD) and use the Carbofilm Technology, whose biocompatible and haemocompatible characteristics are clinically well proven. Datascope has also received exclusive, worldwide rights within the Endovascular Field of Use to the Carbofilm Technology as part of the deal. The product range includes balloon-expandable and self-expanding Stent systems principally for use in the treatment of the iliac arteries, renal arteries and infrapopliteal lesions, as well as balloon systems for use in PTA (Percutaneous Transluminal Angioplasty).

'We are delighted to have found a strategic partner for this business as capable as Datascope of continuing, and expanding, the technological leadership and awareness in the interventional field. Datascope's sales and marketing acumen combined with Sorin's technological and intellectual property platform is a winning combination for this business', said Andre-Michel Ballester, chief executive officer of Sorin Group.

'We believe that Sorin's peripheral vascular stents will be an attractive addition to our product portfolio,” said Dr Antonino Laudani, chief operating officer of Datascope. “We look forward to integrate these new technologies and accelerate product development leveraging our capabilities in marketing, sales, clinical education and training. Our long presence in the cardiovascular surgery call point, as well as our commitment to technology innovation, should enable us to increase and expand peripheral Stent sales”.

The worldwide market for peripheral vascular stents and PTA balloons is estimated at $800 million annually and growing due to an increase of the aging population and higher incidence of diabetes, high blood pressure, obesity and hypercholesterolemia -- all leading causes of PAD.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo